Live Analyst Rating Changes 23246 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andy Chen
WLF

Andy Chen

Wolfe Research
Wall Street Analyst
★★★★★
#245
on 13Foresight · ranked by our own returns
71%
Success Rate
+30.6%
Average Return
27 of 38 calls profitable · +16.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 71% of Andy Chen's ratings turned a profit when each position was held for 1 year — averaging +30.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 10 Hold 2 Sell
Andy's Stock Coverage 32 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
MDGL
Madrigal Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
-4.8% avg upside
33 analysts
$605.00
17.30% Upside
 +5.5% ·
VRTX
Vertex Pharmaceuticals
 Aug 03, 2026 BUY Strong Buy
-15.5% avg upside
62 analysts
$557.00
6.31% Upside
 +12.3% ·
SYRE
Spyre Therapeutics
 Jul 28, 2026 HOLD Strong Buy
-8.7% avg upside
23 analysts
 — +5.4% ·
NTLA
Intellia Therapeutics
 Jul 15, 2026 SELL Buy
+221.7% avg upside
37 analysts
$9.00
25.03% Downside
 +7.2% ·
IONS
Ionis Pharmaceuticals
 Jul 15, 2026 HOLD Strong Buy
+42.3% avg upside
43 analysts
 — +4.0% ·
SRPT
Sarepta Therapeutics
 Jul 08, 2026 BUY Buy
+233.1% avg upside
49 analysts
$27.00
57.18% Upside
 -17.0% ·
CLDX
Celldex
 Jun 14, 2026 BUY Strong Buy
-6.9% avg upside
28 analysts
$44.00
2.31% Upside
 -15.1% ·
ABVX
Abivax SA Sponsored ADR
 Jun 03, 2026 BUY Strong Buy
+6.0% avg upside
15 analysts
$136.00
6.70% Upside
 +39.2% ·
VERA
Vera Therapeutics
 Jun 02, 2026 BUY Strong Buy
+131.1% avg upside
19 analysts
$88.00
178.69% Upside
 +1.0% ·
AVTX
Avalo Therapeutics
 Apr 08, 2026 BUY Strong Buy
+167.3% avg upside
20 analysts
$48.00
142.74% Upside
 +34.8% ·
PHVS
Pharvaris
 Apr 08, 2026 BUY Strong Buy
+33.7% avg upside
15 analysts
$42.00
20.61% Upside
 +26.4% ·
DNTH
Dianthus Therapeutics
 Apr 08, 2026 BUY Strong Buy
-10.4% avg upside
29 analysts
$98.00
12.29% Downside
 +27.8% ·
PALI
Palisade Bio
 Apr 08, 2026 BUY Strong Buy
+1122.9% avg upside
16 analysts
$7.00
233.36% Upside
 +12.8% ·
IMVT
Immunovant
 Apr 06, 2026 BUY Strong Buy
-1.8% avg upside
24 analysts
$47.00
17.84% Upside
 +71.2% ·
MLTX
MoonLake Immunotherapeutics
 Mar 23, 2026 BUY Strong Buy
+75.6% avg upside
20 analysts
$24.00
38.40% Upside
 +2.5% ·
APGE
Apogee Therapeutics
 Jan 07, 2026 HOLD Buy
-8.0% avg upside
19 analysts
 — +70.4% ·
KYMR
Kymera Therapeutics
 Jan 06, 2026 HOLD Strong Buy
-3.4% avg upside
37 analysts
 — +47.8% ·
ARGX
Argenx Se
 Nov 24, 2025 HOLD Strong Buy
-9.3% avg upside
47 analysts
 — -3.0% ·
IVA
Inventiva
 Nov 05, 2025 BUY Strong Buy
+235.3% avg upside
17 analysts
$13.00
173.66% Upside
 +15.8% ·
INSM
Insmed
 Aug 14, 2025 BUY Strong Buy
+33.2% avg upside
37 analysts
$173.00
28.32% Upside
 +4.1% ·
ALNY
Alnylam Pharma
 Aug 04, 2025 HOLD Strong Buy
+46.8% avg upside
51 analysts
 — -47.8% ·
BBIO
BridgeBio Pharma
 Jun 16, 2025 BUY Strong Buy
+11.5% avg upside
34 analysts
$49.00
42.03% Downside
 +62.0% ·
ANAB
AnaptysBio
 May 21, 2025 BUY Strong Buy
+26.8% avg upside
26 analysts
$25.00
54.94% Downside
 +335.5% ·
INCY
Incyte
 Mar 17, 2025 BUY Buy
-11.2% avg upside
47 analysts
$84.00
30.85% Downside
 +51.9% ·
ORKA
Oruka Therapeutics
 Feb 03, 2025 BUY Strong Buy
+20.5% avg upside
16 analysts
$20.00
81.01% Downside
 +152.2% ·
ZBIO
Zenas BioPharma, Inc.
 Feb 03, 2025 BUY Strong Buy
+32.0% avg upside
11 analysts
$19.00
40.66% Downside
 +166.1% ·
CRNX
Crinetics Pharmaceuticals
 Feb 03, 2025 HOLD Buy
-8.1% avg upside
21 analysts
 — +28.8% ·
VRDN
Viridian Therapeutics
 Jun 10, 2024 BUY Strong Buy
+52.1% avg upside
32 analysts
$29.00
25.69% Upside
 +26.2% ·
ROIV
Roivant Sciences
 Feb 14, 2024 BUY Strong Buy
+0.7% avg upside
17 analysts
 — -6.7% ·
CRSP
Crispr Therapeutics AG
 Feb 14, 2024 HOLD Buy
+40.2% avg upside
41 analysts
 — -37.1% ·
STTK
Shattuck Labs
 Oct 25, 2023 BUY Strong Buy
+199.0% avg upside
15 analysts
$4.00
44.07% Downside
 -18.6% ·
AFMDQ
Affimed
 Aug 10, 2023 BUY Buy
+14226263.6% avg upside
16 analysts
$60.00
59999900.01% Upside
 · ·
🔒 27 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andy Chen — Frequently Asked Questions
How accurate are Andy Chen's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Andy's ratings were profitable over a one-year hold, with an average return of +30.0% per rating, or +15.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andy ranked on 13Foresight?
Andy Chen is currently ranked #245 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andy cover?
Andy most recently has ratings on MDGL, VRTX, SYRE, NTLA, IONS, SRPT, CLDX, ABVX, VERA, AVTX, PHVS, DNTH and 20 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.